UNSPSC 51122802: Stirocainide

This classification denotes an antiarrhythmic agent with the molecular formula C22H34N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) LXD20TIK6Y, chemically known as cycloheptanone, 2-(phenylmethylene)-, o-(2-(bis(1-methylethyl)amino)ethyl)oxime, (e,e)- but more generally known as stirocainide, which bears US NIH Compound Identifier 9570767. European Medicines Agency schedules Stirocainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10655MIG.

UNSPSC 51122802 Stirocainide is a Commodity code covering specific pharmaceutical products — in this case a cardiac arrhythmia medication — that state and local governments procure for emergency medical services, hospital pharmacy systems, and public health programs. State and local solicitations under this code target actual pharmaceutical inventory needs: fire rescue departments, health and human services agencies, and cooperative purchasing alliances source branded or generic medications by National Drug Code (NDC) to support emergency medical protocols, pharmacy benefit programs, and multi-jurisdictional distribution networks. Issuing bodies include city purchasing departments (Tampa Fire Rescue through the City of Tampa's Purchasing Department), state health agencies (Texas Health and Human Services Commission), and regional cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, which coordinates across participating states including Oregon). Solicitations typically require vendors to warrant product quality, maintain expiration dates within specified windows (commonly nine months or more from acceptance), arrange timely delivery or pickup of expired stock, provide Safety Data Sheets compliant with OSHA standards, and meet accessibility and federal drug-supply-chain security standards.

Recent opportunities span Florida, Texas, and the upper Midwest. The City of Tampa issued an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications including Labetalol, Epinephrine, Adenosine, and Diltiazem with a response deadline of April 8, 2026 and an estimated contract value of $40,000; the award carried a 5 percent Small Local Business Enterprise (SLBE) sheltered-market bid discount and one-year contract terms with options to renew. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in early April 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, signaling exploratory state-level demand for alternative sourcing models. MMCAP, administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) due March 26, 2026, to establish multi-award contracts for generic pharmaceuticals and OTC products through authorized wholesalers for July 1, 2026 effectiveness, with price competitiveness weighted at 75 percent of evaluation and performance penalties ranging from $200 to $1,500 per violation.